PolarityTE, Inc. (PTE)

NASDAQ: PTE · IEX Real-Time Price · USD
1.59
+0.01 (0.63%)
Jul 7, 2022 1:04 PM EDT - Market open
0.63%
Market Cap 7.10M
Revenue (ttm) 5.44M
Net Income (ttm) -16.55M
Shares Out 4.46M
EPS (ttm) -6.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 96,310
Open 1.61
Previous Close 1.58
Day's Range 1.59 - 1.68
52-Week Range 1.41 - 23.00
Beta 1.14
Analysts Buy
Price Target 24.23 (+1,423.9%)
Earnings Date Aug 11, 2022

About PTE

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision,... [Read more...]

Industry Biotechnology
IPO Date Aug 13, 1999
CEO David Seaburg
Employees 59
Stock Exchange NASDAQ
Ticker Symbol PTE
Full Company Profile

Financial Performance

In 2021, PolarityTE's revenue was $9.40 million, a decrease of -7.13% compared to the previous year's $10.13 million. Losses were -$30.19 million, -29.56% less than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for PTE stock is "Buy." The 12-month stock price forecast is 24.23, which is an increase of 1,423.90% from the latest price.

Price Target
$24.23
(1,423.90% upside)
Analyst Consensus: Buy
Stock Forecasts

News

PolarityTE Announces $8.0 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq...

SALT LAKE CITY , June 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it has entered into s...

PolarityTE to Attend H.C. Wainwright Global Investment Conference

SALT LAKE CITY , May 23, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that Richard Hague, Chief Executive Officer, and Nikolai Sopko, MD, PhD, Chief Scientific Officer, will prese...

PolarityTE to Effectuate 1-for-25 Reverse Stock Split

SALT LAKE CITY , May 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that the Company will effec...

PolarityTE, Inc. (PTE) Reports Q1 Loss, Misses Revenue Estimates

PolarityTE, Inc. (PTE) delivered earnings and revenue surprises of -25% and 12.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PolarityTE Reports First Quarter 2022 Financial Results and Provides Business Update

PolarityTE to host conference call and webcast today, May 16, 2022, at 8:30 a.m. ET SALT LAKE CITY , May 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regene...

PTE Stock Soars 70% Following PolarityTE's New FDA Designation

PolarityTE (PTE) stock is rocketing higher on Friday thanks to positive news from the U.S. Food and Drug Administration (FDA). The post PTE Stock Soars 70% Following PolarityTE's New FDA Designation app...

PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE®

SALT LAKE CITY , May 13, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) desi...

PolarityTE to Report Q1 2021 Financial Results on May 16, 2022

SALT LAKE CITY , May 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the three-month period ended March 31, 2022, by press release on Monday, May 1...

10 Top Penny Stocks To Buy For Under $1 May 2022 Edition

Top penny stocks under $1 to watch in May. The post 10 Top Penny Stocks To Buy For Under $1 May 2022 Edition appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in...

SALT LAKE CITY , May 3, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational us...

Penny Stocks to Buy For Your Watchlist Next Week

Check these three penny stocks out for your watchlist right now The post Penny Stocks to Buy For Your Watchlist Next Week  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock...

Other symbols: LIXTRLX

Best Penny Stocks To Buy Now? 5 Stocks Under $1 To Watch In April

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?

Other symbols: AKBABBIBRQSSESN

PTE Stock Is Rocketing Nearly 100% Today. It's About Time.

PolarityTE has finally gained the traction that it deserves in the midst of an inflection point for the company. The post PTE Stock Is Rocketing Nearly 100% Today.

Why Is PolarityTE Stock Up 85% Today?

PolarityTE Inc (NASDAQ: PTE) shares are surging Tuesday as traders circle bullish commentary from a popular trader in the "FinTwit" community. "FinTwit" is an abbreviated term for "Financial Twitter," w...

Biotech Stocks News: What's Going on With LIXT, PTE, QLGN and ATNM Stocks Today?

Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket.

Other symbols: ATNMLIXTQLGN

Top Penny Stocks to Buy? 3 As Stock Futures Climb Before Market Open

Here's what you need to know about buying penny stocks on April 12th The post Top Penny Stocks to Buy? 3 As Stock Futures Climb Before Market Open appeared first on Penny Stocks to Buy, Picks, News and ...

Other symbols: BCDALIXT

3 Penny Stocks to Watch as Phio Pharma (PHIO) Explodes

Check these three penny stocks out as PHIO stock climbs The post 3 Penny Stocks to Watch as Phio Pharma (PHIO) Explodes  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks....

Other symbols: PHIORIG

PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update

PolarityTE to host conference call and webcast today, March 30, 2022, at 8:30 a.m. ET SALT LAKE CITY , March 30, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing re...

PolarityTE Announces Closing of $5.0 Million Registered Direct Offering

SALT LAKE CITY, March 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) ("PolarityTE" or the "Company"), a biotechnology company developing regenerative tissue products and biomaterials, today ann...

PolarityTE Announces $5.0 Million Registered Direct Offering

SALT LAKE CITY, March 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) ("PolarityTE" or the "Company"), a biotechnology company developing regenerative tissue products and biomaterials, today ann...

PolarityTE to Report Fiscal Year 2021 Financial Results on March 30, 2022

SALT LAKE CITY, March 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the year ended December 31, 2021, by press release on Wednesday, March 30, 2...

PolarityTE's SkinTE Meets Primary, Secondary Goals In Venous Leg Ulcers Trial

PolarityTE Inc (NASDAQ: PTE) has announced results from a multi-center randomized controlled trial evaluating SkinTE for Venous Leg Ulcers (VLU). There were twenty-nine participants, with 14 receiving S...

PolarityTE Announces Allowance of Fourth U.S. Patent

SALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced the U.S. Patent and Tradem...

PolarityTE (PTE) Gets FDA Nod to Begin Pivotal Ulcer Study

PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cutaneous ulcers. PolarityTE plans to start enrollment in the next few months.

FDA Approves PolarityTE's Phase 3 Study Of SkinTE In Chronic Cutaneous Ulcer

The FDA has signed off PolarityTE Inc's (NASDAQ: PTE) investigational new drug (IND) application to evaluate SkinTE to treat chronic cutaneous ulcers.  This follows the Company satisfactorily addressing...